Medtronic

Medtronic was founded in Minneapolis in 1949 by electrical engineer Earl Bakken and his brother-in-law, Palmer Hermundslie, as a business repairing medical electronics. The company’s history describes the early operation as a small workshop that expanded from repairs into custom medical equipment, with the founders’ engineering work closely connected to clinicians and hospitals. [1] [2]

A power outage in Minneapolis on Halloween 1957 exposed the risks of the bulky, outlet-powered pacemakers then used after open-heart surgery. At the request of University of Minnesota heart surgeon C. Walton Lillehei, Bakken developed a wearable, battery-operated pacemaker within four weeks; Medtronic’s history says the company produced its first implantable pacemaker one year later, while a separate company account identifies commercialization of the first implantable pacemaker in 1960. [1] [2]

Medtronic has since developed a broad medical-technology portfolio. Its current key-facts page says its technologies address more than 70 health conditions through cardiovascular, medical-surgical and neuroscience portfolios, including electrophysiology, interventional cardiology, peripheral vascular health, acute care and monitoring, endoscopy, surgery, cranial and spinal technologies, neuromodulation and neurovascular care. The page reports FY25 figures of 174 active clinical trials, $2.7 billion in research-and-development investment and more than 41,000 active patent matters. [3]

The company’s current corporate structure also reflects its international scale. Following the 2014 agreement to acquire Covidien, Medtronic said Medtronic plc would be the parent company, with principal executive offices in Ireland and operational headquarters in Minneapolis. This supports retaining Minneapolis as the operational headquarters in the entity record while distinguishing it from the parent company’s Irish administrative headquarters. [4]

Medtronic’s inclusion in this database is associated with its medical-technology partnerships and clinical ecosystem, but its own identity is rooted in engineering-led device development. The company’s current key-facts page says its technologies have served more than 74 million patients and that its mission is pursued through products and therapies spanning the three listed solution portfolios. [3]